Literature DB >> 11431710

Molecular pathology of endometrial hyperplasia and carcinoma.

X Matias-Guiu1, L Catasus, E Bussaglia, H Lagarda, A Garcia, C Pons, J Muñoz, R Argüelles, P Machin, J Prat.   

Abstract

Four different genetic abnormalities may occur in endometrioid adenocarcinomas of the endometrium (mircosatellite instability and mutations in the PTEN, k-RAS and beta-catenin genes), whereas nonendometrioid carcinomas of the endometrium often have p53 mutations and loss of heterozygosity on several chromosomes. Occasionally, a nonendometrioid carcinoma may develop as a result of dedifferentiation of a preexisting endometrioid carcinoma; in such a case, the tumor exhibits overlapping clinical, morphologic, immunohistochemical, and molecular features of the 2 types. The insaturation of microsatellite instability in endometrial carcinogenesis seems to occur late in the transition from complex hyperplasia to carcinoma, and it is preceded by progressive inactivation of MLH-1 by promoter hypermethylation. Moreover, the endometrioid adenocarcinomas that exhibit microsatellite instability show a stepwise progressive accumulation of secondary mutations in oncogenes and tumor suppressor genes that contain short-tandem repeats in their coding sequences. Mutations in the PTEN and k-RAS genes are also frequent in endometrioid adenocarcinomas of the endometrium, particularly in the tumors that exhibit microsatellite instability, whereas beta-catenin mutations do not seem to be associated with such a phenomenon. Copyright 2001 by W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431710     DOI: 10.1053/hupa.2001.25929

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  47 in total

1.  An orderly retreat: Dedifferentiation is a regulated process.

Authors:  Mariko Katoh; Chad Shaw; Qikai Xu; Nancy Van Driessche; Takahiro Morio; Hidekazu Kuwayama; Shinji Obara; Hideko Urushihara; Yoshimasa Tanaka; Gad Shaulsky
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-21       Impact factor: 11.205

2.  A novel three-dimensional culture system of polarized epithelial cells to study endometrial carcinogenesis.

Authors:  Núria Eritja; David Llobet; Mónica Domingo; Maria Santacana; Andree Yeramian; Xavier Matias-Guiu; Xavi Dolcet
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

3.  CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation.

Authors:  Judit Pallares; David Llobet; Maria Santacana; Nuria Eritja; Ana Velasco; Dolors Cuevas; Susana Lopez; Victor Palomar-Asenjo; Andree Yeramian; Xavier Dolcet; Xavier Matias-Guiu
Journal:  Am J Pathol       Date:  2008-12-04       Impact factor: 4.307

4.  Alteration of the k-ras gene expression in atypical and nonatypical hyperplastic endometrium.

Authors:  Narges Izadi-Mood; Soheila Sarmadi; Behzad Rostamnasl
Journal:  Iran J Cancer Prev       Date:  2013

Review 5.  [Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology].

Authors:  S Lax
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

6.  The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma.

Authors:  Bozena Konopka; Aneta Janiec-Jankowska; Zygmunt Paszko; Marian Goluda
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-09       Impact factor: 4.553

7.  Molecular profiling of endometrial malignancies.

Authors:  Norasate Samarnthai; Kevin Hall; I-Tien Yeh
Journal:  Obstet Gynecol Int       Date:  2010-03-28

8.  DcR1 expression in endometrial carcinomas.

Authors:  Jordi Tarragona; Nuria Llecha; Maria Santacana; Susana Lopez; Sonia Gatius; David Llobet; Xavier Dolcet; Victor Palomar-Asenjo; Francisco Javier Gonzalez-Tallada; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2009-11-20       Impact factor: 4.064

Review 9.  Application of DNA methylation biomarkers for endometrial cancer management.

Authors:  Shi-Wen Jiang; Jinping Li; Karl Podratz; Sean Dowdy
Journal:  Expert Rev Mol Diagn       Date:  2008-09       Impact factor: 5.225

10.  Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells.

Authors:  Laura Bergadà; Annabel Sorolla; Andree Yeramian; Nuria Eritja; Cristina Mirantes; Xavier Matias-Guiu; Xavier Dolcet
Journal:  Mol Oncol       Date:  2013-03-28       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.